Patents by Inventor Detlev Suelzle
Detlev Suelzle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240182452Abstract: The present invention provides dihydropyridazinone compounds of general formula (I) in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 28, 2023Publication date: June 6, 2024Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Detlev SÜLZLE, Timothy LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON
-
Publication number: 20240150277Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.Type: ApplicationFiled: August 31, 2023Publication date: May 9, 2024Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Knut EIS, Timo STELLFELD, Léa Aurelie BOUCHÉ, Elisabeth POOK, Joseph Peter BLUCK, Philip LIENAU, Constantia PANTELIDOU, Isabel Sophie JERCHEL-FURAU, Ulf BRÜEGGEMEIER, Sven CHRISTIAN, Detlev SÜLZLE, Anders Roland FRIBERG, Simon HOLTON, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Douglas ORSI, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE
-
Publication number: 20230416249Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: May 10, 2023Publication date: December 28, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Ulrich KLAR, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Publication number: 20230365554Abstract: Compounds of formula (I), process for their production and their use as pharmaceuticals.Type: ApplicationFiled: July 27, 2021Publication date: November 16, 2023Inventors: Volker Schulze, Anne Mengel, Adelaide Clara Faria Alvares De Lemos, Ulrike Rauh, Ulf Bömer, Roman Hillig, Christian Lechner, Jeremie Xavier G. Mortier, Detlev Sülzle, Stefan Kaulfuss, Steven Corsello, Katarzyna Handing, Alisha Caliman, Amael Madec
-
Patent number: 11773070Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: July 14, 2022Date of Patent: October 3, 2023Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
-
Publication number: 20230113481Abstract: An aqueous pharmaceutical composition including compound having the formula of tetragadolinium[4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10- tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.Type: ApplicationFiled: November 2, 2022Publication date: April 13, 2023Inventors: MARKUS BERGER, JESSICA LOHRKE, CHRISTOPH-STEPHAN HILGER, GREGOR JOST, THOMAS FRENZEL, DETLEV SUELZLE, JOHANNES PLATZEK, OLAF PANKNIN, HUBERTUS PIETSCH
-
Publication number: 20230064983Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: ApplicationFiled: September 22, 2022Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Publication number: 20230017200Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 11, 2022Publication date: January 19, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
-
Publication number: 20220396554Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: July 14, 2022Publication date: December 15, 2022Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
-
Patent number: 11491245Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.Type: GrantFiled: July 27, 2020Date of Patent: November 8, 2022Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Markus Berger, Jessica Lohrke, Christoph-Stephan Hilger, Gregor Jost, Thomas Frenzel, Detlev Suelzle, Johannes Platzek, Olaf Panknin, Hubertus Pietsch
-
Publication number: 20220298157Abstract: Compounds of formula (I), formula (I), processes for their production and their R use as pharmaceuticals.Type: ApplicationFiled: April 22, 2020Publication date: September 22, 2022Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
-
Patent number: 11427553Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 2, 2018Date of Patent: August 30, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
-
Patent number: 11339157Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.Type: GrantFiled: October 23, 2018Date of Patent: May 24, 2022Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.Inventors: Stephan Siegel, Franziska Siegel, Volker Schulze, Markus Berger, Keith Graham, Ulrich Klar, Knut Eis, Detlev Sülzle, Ulf Bömer, Daniel Korr, Kirstin Petersen, Ursula Mönning, Uwe Eberspächer, Dieter Moosmayer, Matthew Meyerson, Heidi Greulich, Bethany Kaplan, Hassan Youssef Harb, Phi Manh Dinh
-
Patent number: 11311520Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.Type: GrantFiled: August 3, 2020Date of Patent: April 26, 2022Assignees: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Ulrich Klar, Rolf Bohlmann, Heike Schäcke, Detlev Sülzle, Stephan Menz, Olaf Panknin
-
Publication number: 20210353630Abstract: The present invention includes name compounds of general formula (I): (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.Type: ApplicationFiled: July 30, 2021Publication date: November 18, 2021Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.Inventors: Stefan Nikolaus GRADL, Manuel ELLERMANN, Philip LIENAU, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU
-
Publication number: 20210085656Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 3, 2020Publication date: March 25, 2021Applicants: Bayer Pharma Aktiengesellschaft, Bayer AktiengesellschaftInventors: Ulrich KLAR, Rolf BOHLMANN, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ, Olaf PANKNIN
-
Publication number: 20210017174Abstract: The present invention covers heterocyclic compounds of general formula (I) in which T, U, Y, Z, R1 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer disorders, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: March 1, 2019Publication date: January 21, 2021Inventors: Duy NGUYEN, Lars WORTMANN, Adelaide Clara FARIA ALVARES DE LEMOS, Ulf BOEMER, Detlev SUELZLE, Simon HOLTON, Christian LECHNER
-
Publication number: 20200369633Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: August 2, 2018Publication date: November 26, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
-
Publication number: 20200353104Abstract: A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.Type: ApplicationFiled: July 27, 2020Publication date: November 12, 2020Inventors: MARKUS BERGER, JESSICA LOHRKE, CHRISTOPH-STEPHAN HILGER, GREGOR JOST, THOMAS FRENZEL, DETLEV SUELZLE, JOHANNES PLATZEK, OLAF PANKNIN, HUBERTUS PIETSCH
-
Publication number: 20200247783Abstract: The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I): The present invention provides 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives of formula (I):Type: ApplicationFiled: August 2, 2018Publication date: August 6, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Detlev Sülzle, Timothy Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson